APCCA2019_015_Session 3A: The Future Potential of Immunotherapy in Biliary Tract Cancer

APCCA2019_015_Session 3A: The Future Potential of Immunotherapy in Biliary Tract Cancer

Future developments in immunotherapy for treatment of biliary tract cancerПодробнее

Future developments in immunotherapy for treatment of biliary tract cancer

APCCA2019_019_Session 3B: Guidelines for Care of the Patient Receiving ChemotherapyПодробнее

APCCA2019_019_Session 3B: Guidelines for Care of the Patient Receiving Chemotherapy

AC23 - Session III: Immunotherapy: Where we are and where we're going?Подробнее

AC23 - Session III: Immunotherapy: Where we are and where we're going?

Evolution of HER2-Targeted Therapy in Biliary Tract CancerПодробнее

Evolution of HER2-Targeted Therapy in Biliary Tract Cancer

APCCA2019_016_Session 3A: Precision Medicine on the Horizon for CholangiocarcinomaПодробнее

APCCA2019_016_Session 3A: Precision Medicine on the Horizon for Cholangiocarcinoma

Immunochemotherapy: The Future of Cancer TreatmentПодробнее

Immunochemotherapy: The Future of Cancer Treatment

Global EP 3.0 Summit: Physician Presentations May 7 2020Подробнее

Global EP 3.0 Summit: Physician Presentations May 7 2020

Video Capsule: Evolving Therapeutic Approach in Advanced Unresectable Biliary Tract CancerПодробнее

Video Capsule: Evolving Therapeutic Approach in Advanced Unresectable Biliary Tract Cancer

Disease avatars : Chasing precision medicine through cell reprogramming | Giuseppe Testa | TEDxRomaПодробнее

Disease avatars : Chasing precision medicine through cell reprogramming | Giuseppe Testa | TEDxRoma

Significance of KEYNOTE-045 Trial of Pembrolizumab vs Chemotherapy in Urothelial CarcinomaПодробнее

Significance of KEYNOTE-045 Trial of Pembrolizumab vs Chemotherapy in Urothelial Carcinoma

Global EP 3.0 Summit: Engaging Case Studies May 5 2020Подробнее

Global EP 3.0 Summit: Engaging Case Studies May 5 2020